Company Profile
Elixir Medical is a US-based manufacturer of coronary and peripheral vascular devices, headquartered in Milpitas, California, USA. Founded in 2005, the company operates as an independent, privately-held entity, serving interventional cardiology and peripheral vascular markets across Europe, Asia-Pacific, and the Middle East.
Core Products ＆ Technologies
Coronary Bioadaptor Systems
• DynamX Coronary Bioadaptor System: CE-marked implant designed to unlock after healing, restoring vessel pulsatility, compliance, and adaptive remodeling
• DynamX Sirolimus-Eluting Coronary Bioadaptor: FDA Breakthrough Device Designation for symptomatic ischemic heart disease; investigational in the US
Drug-Eluting Stent Systems
• DESyne X2 Novolimus Eluting Coronary Stent System: CE-marked device featuring ultrathin durable polymer and low-dose novolimus for coronary artery disease
• DESyne Nx Novolimus Eluting Coronary Stent System: IDE-approved for the EXCELLA III pivotal trial in the United States
Intravascular Lithotripsy Systems
• LithiX Hertz Contact Lithotripsy System: CE-marked intravascular lithotripsy platform for treating calcified coronary lesions
Market Position ＆ Certifications
Elixir Medical holds a pioneering position in the global coronary bioadaptor market, competing with Medtronic (Resolute Onyx DES) in traditional drug-eluting stents and ShockWave Medical in intravascular lithotripsy. Key strengths include:
• 20+ years of US engineering heritage in cardiovascular devices
• Bioadaptor Technology: Unique unlockable helical design restoring hemodynamic modulation and vessel viability
• Regulatory compliance: CE marked; FDA Breakthrough Device Designation for DynamX Coronary and BTK systems
• Global service network: Localized technical support across major markets
Corporate Timeline
2005 — Founded in Milpitas, CA to develop drug-device cardiovascular treatments
2013 — FDA IDE approval granted for DESyne Nx EXCELLA III pivotal trial
2019 — Closed Series G financing at $38.5M, total raised exceeding $171M
2024 — FDA Breakthrough Device Designation awarded to DynamX Coronary and DynamX BTK systems
2025 — Named to Fast Company＇s World＇s Most Innovative Companies list; TCT presentation of BIOADAPTOR RCT two-year data
Target Markets ＆ Applications
• Coronary Artery Disease (CAD): DynamX Bioadaptor and DESyne stent systems for de novo and complex lesions
• Chronic Limb-Threatening Ischemia (CLTI): DynamX BTK Bioadaptor for below-the-knee revascularization
• Calcified Coronary Lesions: LithiX Hertz Contact Lithotripsy System for vessel preparation
Contact Information
Global Headquarters
Address: 920 N. McCarthy Blvd., Milpitas, CA 95035, USA
Parent Company
Elixir Medical Corporation operates as an independent, privately-held entity with no parent company or publicly traded stock.
Website: elixirmedical.com
Investor Relations: Private company; financial partner The Invus Group
